PARTNERSHIPS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

The strategic slowdown in the diagnostics sector continues. Late February to March was relatively light in both deal volume and value, especially compared to the same period in 2017. As usual, the … [Read more...]

MARKETING

Theranos & Its CEO Settle Stock Fraud Charges with SEC

Seven years ago, Theranos was a $9 billion dynamo seemingly on the precipice of blowing the blood testing market wide open. Today, the company and its CEO and founder, Elizabeth Holmes, are a … [Read more...]

DISTRIBUTION AGREEMENTS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

Based on the early returns, the market analysts that predicted 2018 would see a slowdown in strategic Dx deal making appear to be right. But while deal volume was low on both the M&A and alliance … [Read more...]

MARKETING

Theranos & Its CEO Settle Stock Fraud Charges with SEC

CMS; The Arizona Attorney General; Walgreen's; Its own shareholders. And now Theranos has a new legal adversary: the US Securities Exchange Commission which has charged Theranos and its founder … [Read more...]

INTELLECTUAL PROPERTY

Happy Endings: Guardant & Foundation Make Sweet Lemonade Out of False Advertising Lemons

In June 2017, Guardant Health sued Foundation Medicine for making false statements about the Guardant360 test in its advertisements for the FoundationACT liquid biopsy genomic profiling test. … [Read more...]

PARTNERSHIPS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

As the calendar turned to 2018 and Medicare turned to PAMA, diagnostic deal making revved up. Deal volume was relatively heavy although short on drama. But what looks to be a big year is just … [Read more...]

MERGERS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

Good news for any of you who slept through December 2017: You didn't miss much—at least as far as blockbuster strategic deals in the clinical laboratory space are concerned. M&AIn contrast to … [Read more...]

DISTRIBUTION AGREEMENTS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

The pattern of high volume and relatively low impact continued with strategic alliances outnumbering acquisitions at rate of roughly 3:1. M&A Following the trio of mega-deal closings, … [Read more...]

MARKETING

Report: Outreach Labs Remain Profitable Despite Antiquated Systems & Lack of Exec Respect

Hidden within the basement of your average hospital is a $24 million business, one that provides a top quality, must-have service and operates at a margin of around 25% to 30%. That business is the … [Read more...]

GREAT TRANSITION UNDERWAY

Laboratories Increasing Customer-Focus

Laboratories have always had a strong service component—both for their referring physicians and the patient. However, laboratories are now in the midst of a great transition, where a concerted … [Read more...]


(-0000g2)